PCSK9 inhibition for acute arterial events: more than LDL lowering

Eur Heart J. 2021 Dec 14;42(47):4830-4832. doi: 10.1093/eurheartj/ehab739.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Anticholesteremic Agents* / therapeutic use
  • Cholesterol, LDL
  • Humans
  • Proprotein Convertase 9*

Substances

  • Anticholesteremic Agents
  • Cholesterol, LDL
  • PCSK9 protein, human
  • Proprotein Convertase 9